biostudies-literatureUnknown21(1)Yamashita K<h4>Background</h4>Levodopa-carbidopa intestinal gel (LCIG) treatment, a unique drug delivery system for patients with advanced Parkinson's disease (PD), is covered by health insurance in Japan since September 2016. Various LCIG procedure/device-associated adverse events (AEs) have been reported; however, reports on their treatment have been limited. This is the first multicenter study to clarify the frequency and timing of device-related AEs.<h4>Methods</h4>Between September 2016 and December 2018, 104 patients introduced to the LCIG treatment for advanced PD in 11 hospitals were included. The patients' characteristics, AEs incidence, AEs time, and tube exchange time were investigated.<h4>Results</h4>The median follow-up period was 21.5 months. Minor AE cases were 29.4%, whereas major AE BMC neurology242https://www.ebi.ac.uk/biostudies/studies/S-EPMC8228941biostudies-literatureThe impact of tube replacement timing during LCIG therapy on PEG-J associated adverse events: a retrospective multicenter observational study.PMC8228941Ikeda YFurukawa KJin XSuzuki TKoike TFurune SFujioka SYube YSato YTsuboi YYamazaki YUehara TMurakami HKato MKubota EFukuchi TYamashita KfalseThe impact of tube replacement timing during LCIG therapy on PEG-J associated adverse events: a retrospective multicenter observational study.<h4>Background</h4>Levodopa-carbidopa intestinal gel (LCIG) treatment, a unique drug delivery system for patients with advanced Parkinson's disease (PD), is covered by health insurance in Japan since September 2016. Various LCIG procedure/device-associated adverse events (AEs) have been reported; however, reports on their treatment have been limited. This is the first multicenter study to clarify the frequency and timing of device-related AEs.<h4>Methods</h4>Between September 2016 and December 2018, 104 patients introduced to the LCIG treatment for advanced PD in 11 hospitals were included. The patients' characteristics, AEs incidence, AEs time, and tube exchange time were investigated.<h4>Results</h4>The median follow-up period was 21.5 months. Minor AE cases were 29.4%, whereas major AE 2021-01-01T00:00:00Z2021 Jun2025-04-26T00:30:49.373Z2022-02-10T17:14:18.229ZS-EPMC82289413417200210.1186/s12883-021-02269-7